Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Givinostat Effect on Midazolam and Dabigatran PK (Part 1)
NCT05492318Phase 1Completed
- Sponsor
- Italfarmaco
- Start
- Mar 2022
- Primary completion
- May 2022
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of givinostat in Duchenne muscular dystrophy (DMD), sponsored by Italfarmaco. Primary endpoints: Maximum Plasma Concentration (Cmax) for Midazolam at 24 hours, Maximum Plasma Concentration (Cmax) for Dabigatran at 72 hours and 6 more. Started Mar 2022; status: completed.
02
Drugs
givinostat
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT05492318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05492318.